Article
CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Journal of psychopharmacology (Oxford, England) - 1 Mar 2012
Huezo-Diaz Patricia, Perroud Nader, Spencer Edgar P, Smith Rebecca, Sim Sarah, Virding Susanne, Uher Rudolf, Gunasinghe Cerisse, Gray Jo, Campbell Desmond, Hauser Joanna, Maier Wolfgang, Marusic Andrej, Rietschel Marcella, Perez Jorge, Giovannini Caterina, Mors Ole, Mendlewicz Julien, McGuffin Peter, Farmer Anne E, Ingelman-Sundberg Magnus, Craig Ian W, Aitchison Katherine J
Abstract excerpt
In vitro work shows CYP2C19 and CYP2D6 contribute to the metabolism of escitalopram to its primary metabolite, N-desmethylescitalopram. We report the effect of CYP2C19 and CYP2D6 genotypes on steady state morning concentrations of escitalopram and N-desmethylescitalopram and the ratio of this metabolite to the parent drug in 196 adult patients with depression in GENDEP, a clinical pharmacogenomic trial. Subjects...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
